الفهرس | Only 14 pages are availabe for public view |
Abstract Acute coronary syndrome (ACS) is the umbrella term of STEMI, NSTEMI and UA and it is the progression of coronary atherosclerosis which in some cases can remain clinically silent for years, decades, or even for life, in contrast, other cases exhibit ACS at a certain point in their life. The pathogenesis of ACS is mediated by disruption of an atherosclerotic plaque or by thrombus formation.The proinflammatory markers and on top of them IL-6 and CRP were confirmed in many studies to affect the coronary state and the outcome of ACS patients. The high serum levels of these proinflammatory markers were found to be associated with severe condition and bad cardiac outcome such as heart failure, rehospitalization and even death. This study was directed to measure the serum levels of IL-6 and CRP in ACS patients shortly after the attack and to correlate the IL-6 levels with adverse cardiovascular outcomes after following up those patients for a short-time (30 days).This study was conducted over a period of 12 months from september 2016 to september 2017 on 90 patients diagnosed as ACS. Blood samples were collected from patients in the first 48 hs after admission and serum was separated then IL-6 and CRP levels were measured by ELISA and turbidimetry respectively. In this study we found a significant correlation between IL-6 and CRP levels and the outcome of ACS. The higher IL-6 and CRP levels were found in patients who developed bad outcome and within those patients, the IL-6 and CRP levels were found to be higher in patients who had a stent than who hadn’t. We concluded from this study that IL-6 and CRP levels are higher in patients who are more likely to develop adverse cardiac outcome so, their levels could be helpful in the prognosis of ACS patients and in determination of patients who are at risk of developing major adverse cardiac outcome in short term and who in turn can benefit more from early intervention than others. |